Search Within

Nicole Lamanna

Formats
  1. Meeting Abstract (39)
  2. Journal Article (19)
  3. Book Section (2)
Groups
  1. Center for Hematologic Malignancies (35)
  2. Department of Medicine (35)
  3. Hematologic Malignancies, Division of (35)
  4. Adult Leukemia (23)
  5. GSK Faculty (19)
  6. Hematologic Malignancies Research (19)

More Groups

People
  1. Mark Weiss (24)
  2. Peter Maslak (18)
  3. Joseph Jurcic (17)
  4. David Scheinberg (13)
  5. Mark Heaney (12)
  6. Renier Brentjens (12)

More People

Years
  1. 2015 (1)
  2. 2014 (7)
  3. 2013 (7)
  4. 2012 (9)
  5. 2011 (4)
  6. 2010 (2)

More Years

Publications
  1. Blood (19)
  2. Journal of Clinical Oncology (15)
  3. Current Hematologic Malignancy Reports (5)
  4. Current Oncology Reports (2)
  5. Haematologica (2)
  6. Advances in Pharmacology (1)

More Publications

Publishers
  1. American Society of Hematology (19)
  2. American Society of Clinical Oncology (15)
  3. Springer (7)
  4. American Association for Cancer Research (2)
  5. CMP Healthcare Media (2)
  6. Elsevier Inc. (2)

More Publishers

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chronic lymphocytic leukemia
    Book Section

    Wierda, W. G.; Lamanna, N.; Weiss, M. A.
    In Pazdur, R.; Wagman, L. D.; Camphausen, K. A.; Hoskins, W. J. (Eds.) Cancer Management: A Multidisciplinary Approach. 12th ed (2009)

    Fulltext@MSK | Save
  • Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.; Weiss, M. A.
    Current Hematologic Malignancy Reports (2009)

    Fulltext@MSK | Save
  • Pentostatin treatment combinations in chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.; Kay, N. E.
    Clinical Advances in Hematology & Oncology (2009)

    Fulltext@MSK | Save
  • Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses
    Journal Article

    Lamanna, N.; Jurcic, J. G.; Noy, A.; Maslak, P.; Gencarelli, A. N.; Panageas, K. S.; Heaney, M. L.; Brentjens, R. J.; Golde, D. W.; Scheinberg, D. A.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia
    Journal Article

    Jain, N.; Lamanna, N.
    Current Oncology Reports (2009)

    Fulltext@MSK | Save
  • BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience
    Meeting Abstract

    Elfiky, A.; Saif, M. W.; Beeram, M.; O'Brien, S.; Lammanna, N.; Castro, J. E.; Woodworth, J.; Perea, R.; Storgard, C.; Von Hoff, D. D.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Pentostatin in chronic lymphocytic leukemia
    Journal Article

    Sauter, C.; Lamanna, N.; Weiss, M. A.
    Expert Opinion on Drug Metabolism and Toxicology (2008)

    Fulltext@MSK | Save
  • Chronic lymphocytic leukemia
    Book Section

    Wierda, W. G.; Lamanna, N.; Cortes, J. E.; Weiss, M. A.
    In Pazdur, R.; Coia, L. R.; Hoskins, W. J.; Wagman, L. D. (Eds.) Cancer Management: A Multidisciplinary Approach. 10th ed (2007)

    Fulltext@MSK | Save
  • Phase 1 experience with BIIB021, an oral, synthetic, non-ansamycin Hsp90 inhibitor
    Meeting Abstract

    von Hoff, D.; Beeram, M.; Brien, S. O.; Lamanna, N.; Castro, J.; Borad, M.; Burrows, F.; Trone, D.; Woodworth, J.; Tangri, S.; more...
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, rituximab, and mitoxantrone (PCRM): A new highly active regimen for patients with chronic lymphocytic leukemia (CLL) previously treated with PCR or FCR
    Meeting Abstract

    Lamanna, N.; Heaney, M. L.; Brentjens, R. J.; Jurcic, J. G.; Weiss, M. A.
    Blood (2007)

    Fulltext@MSK | Save